BIOMAT Database Logo BIOMAT Database Logo

[Serum concentrations of procainamide during treatment with ordinary and sustained-release tablets]. 1976

P Henningsen, and H B Laursen, and B D Christiansen, and J Moller

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009203 Myocardial Infarction NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). Cardiovascular Stroke,Heart Attack,Myocardial Infarct,Cardiovascular Strokes,Heart Attacks,Infarct, Myocardial,Infarction, Myocardial,Infarctions, Myocardial,Infarcts, Myocardial,Myocardial Infarctions,Myocardial Infarcts,Stroke, Cardiovascular,Strokes, Cardiovascular
D011342 Procainamide A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. Procaine Amide,Apo-Procainamide,Biocoryl,Novocainamide,Novocamid,Procainamide Hydrochloride,Procamide,Procan,Procan SR,Procanbid,Pronestyl,Rhythmin,Amide, Procaine,Hydrochloride, Procainamide
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000208 Acute Disease Disease having a short and relatively severe course. Acute Diseases,Disease, Acute,Diseases, Acute
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D001145 Arrhythmias, Cardiac Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac

Related Publications

P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Sustained-release procainamide: use of serum concentrations to determine dosage.
October 1985, Southern medical journal,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Lithium absorption from ordinary and from sustained-release tablets.
December 1972, Acta pharmaceutica Suecica,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Prediction of steady-state trough serum procainamide concentrations after administration of a sustained-release procainamide preparation.
January 1986, Therapeutic drug monitoring,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Dosage, plasms concentration and antiarrhythmic effect of procainamide in sustained-release tablets.
March 1974, Acta medica Scandinavica,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Serum drug concentrations in patients with ischemic heart disease after administration of a sustained release procainamide preparation.
January 1983, Angiology,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Sustained-release procainamide and neutropenia.
September 1984, Annals of internal medicine,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Predicting plasma procainamide concentrations resulting from a sustained-release preparation.
January 1985, Clinical pharmacy,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Conversion from intravenous procainamide to oral sustained release tablets in cardiac patients.
January 1990, The Canadian journal of cardiology,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Bioequivalency of sustained-release procainamide.
June 1984, Drug intelligence & clinical pharmacy,
P Henningsen, and H B Laursen, and B D Christiansen, and J Moller
Procainamide in plasma following administration of sustained-release tablets in acute myocardial infarction.
March 1975, Current therapeutic research, clinical and experimental,
Copied contents to your clipboard!